Alzheimer’s Association International Conference 2017 London
CTAD: Clinical Trials on Alzheimer’s Disease Nov 1-4, 2017 Boston
Alzheimer’s Drug Discovery Foundation Fall Symposium October 27, 2017 New York City
West Michigan Medical Innovation Summit October 3, 2017 MSU College of Human Medicine, Grand Rapids, MI
brainSTEM Saturday, September 16, 2017 Grand Rapids Public Museum
Rodman & Renshaw Investment Conference September 10-12, 2017 New York City
Alzheimer’s Drug Discovery Foundation September 7, 2017 New York City
BIO June 2017 San Diego


GRBJ December 12, 2016 2016 Newsmaker of the Year finalists
PM360 December 21, 2016 Innovators 2016: Startups


Neurotherapeutics April 12, 2017 National Institutes of Health Blueprint Neurotherapeutics Network: Results to Date and Path Forward
FirceBiotech March 6, 2017 ‘Master genes’ may explain why some NFL players develop brain diseases
BioSpace January 17, 2017 Company Appoints Richard Erwin As Vice President, Clinical Operations
Yahoo! January 17, 2017 Tetra Discovery Partners Appoints Richard Erwin as Vice President, Clinical Operations
CEO CFO Magazine January 9, 2017 Type 4D Phosphodiesterase (PDE4D) Modulator Currently in Clinical Trials
Life Science Leader December 1, 2016 Company Leaders Tackle The New Year’s Toughest Macro Challenges
Xconomy November 30, 2016 Tetra Discovery Raises $10M Series A, Advances Alzheimer’s Drug November 29, 2016 Drug startup secures $10M
MiBiz October 30, 2016 Partner, Sell or IPO? West Michigan life science companies weigh complex next steps
MiBiz August 5, 2016 Tetra Discovery Partners secures $4.28M in VC funding for new drug July 26, 2016 Local drug developer targets traumatic brain injury July 6, 2016 Tetra’s experimental med may boost memory after brain injury
MiBiz July 6, 2016 Experimental drug from Tetra Discovery Partners may treat traumatic brain injury May 26, 2016 Making it in Grand Rapids: How the GR Smart Zone is evolving December 30, 2015 New NIH-funded memory drug moves into Phase 1 Clinical study December 30, 2015 Tetra candidate backed by NIH’s Blueprint enters clinic
MiBiz December 18, 2015 Tetra Discovery to launch clinical trials on Alzheimer’s druge with MPI’s Jasper Clinic December 9, 2015 Grand Rapids Firm to begin Trials on Alzheimer’s drug that improves memory January 29, 2015 Tetra Discovery Partners October 31, 2014 Tetra Discovery Partners lands funding
MiBiz October 26, 2014 Financing from Johnson & Johnson Development Corporation and Grand Angels
Grand Rapids Business Journal August 22, 2014 Additional financing by Grand Angels
Startup: Pharma & MedTech Business Intelligence December 23, 2013
Grand Rapids Business Journal September 30, 2013 Initial investment from Grand Angels
MiBiz November 25, 2012 Michigan’s Life Sciences industry on the rise June 20, 2012 NIH Blueprint Therapeutics grant awarded to Tetra Discovery Partners


Tetra Discovery Partners Appoints Richard Erwin as Vice President, Clinical Operations

Grand Rapids, MI (January 17, 2017) – Tetra Discovery Partners today announced the appointment of Richard M. Erwin as Vice President, Clinical Operations. He joins the company from Catalyst Pharmaceuticals, where he was Executive Director, Clinical Project Management. more

Tetra Discovery Partners Announces Positive Results from Phase 1 Studies of Cognition Drug Candidate, BPN14770

Grand Rapids, MI (December 19, 2016) – Tetra Discovery Partners today announced positive results from two Phase 1 studies of its selective PDE4D allosteric inhibitor drug candidate, BPN14770. The double blind, placebo-controlled, dose-ranging studies were designed primarily to study the safety and pharmacokinetics of single ascending doses and multiple ascending doses of BPN14770 in healthy young and elderly volunteers. more

Tetra Discovery Partners Raises $10 Million through Series A Financing and Two National Institutes of Health Grants — New funds help advance memory drug candidate BPN14770 in Alzheimer’s disease and support Tetra’s development effort in depression

Grand Rapids, MI (November 29, 2016) – Tetra Discovery Partners today announced that it has closed a $5 million Series A Venture Financing. The financing was co-led by the Apjohn Group and Grand Angels, with the participation of previous investors as well as Dolby Family Ventures, the Alzheimer’s Drug Discovery Foundation, and other private investors. With conversion of two debt rounds, the total Series A financing rolls up to $7,277,825.  more

Research from University of Miami and Tetra Discovery Shows Potential of Novel Drug to Improve Memory after Traumatic Brain Injury:  University of Miami Miller School of Medicine / The Miami Project to Cure Paralysis and Tetra Discovery Partners Study Published in the Journal of Neuroscience

Miami, FL – July 6, 2016: Treating rats with an experimental drug at three months following a traumatic brain injury (TBI) improves their learning memory ability, as reported in a new study published online today in the July edition of The Journal of Neuroscience.  The drug, a selective phosphodiesterase 4 subtype inhibitor (PDE4B), is currently under development by Tetra Discovery Partners, a privately held biotechnology company and is being tested as a potential therapy for TBI by University of Miami / Miami Project researchers.  more

Tetra Discovery Partners affirms the significant role Michigan investment offers

Grand Rapids, MI, May 31, 2016:   Dr. Mark E. Gurney, CEO and Chairman of Tetra Discovery Partners LLC, was asked to participate in the Michigan Biosciences Day at the Capitol 2016 in Lansing, Michigan.  MichBIO is the statewide voice of Michigan’s biosciences industry.  During meetings with legislative staff for State Senators Dave Hildenbrand and Margaret O’Brien and State Representative David LaGrand, Dr. Gurney emphasized the importance of state-based investment in early stage biotechnology startups.  Dr. Gurney based his comments on his own experience launching Tetra Discovery Partners in 2011 “with $2,000 in a business checking account,” he said.   more

Tetra Discovery Advances Alzheimer’s Treatment Candidate BPN14770 to Phase I Multiple Ascending Dose Trial

GRAND RAPIDS, MI, April 1, 2016: Tetra Discovery Partners (“Tetra”) today announced that the company has successfully completed its initial Phase 1 single ascending dose (SAD) study of BPN14770 safety in 32 healthy volunteers.  BPN14770 is the company’s experimental treatment aimed at improving memory and slowing the progression of Alzheimer’s disease.  Tetra plans to begin its second Phase 1 trial of BPN14770 in June, which will study multiple ascending doses (MAD).  more

Tetra Discovery Initiates Phase 1 Study of BPN14770, Under Development for Treatment and Prevention of Alzheimer’s Disease

Grand Rapids, MI (December 9, 2015): Tetra Discovery Partners (“Tetra”) today announced that the company has initiated human Phase 1 safety trials of its lead compound BPN14770, which Tetra is developing as a potential treatment to both improve memory and slow the progression of Alzheimer’s disease.   more

Tetra Discovery Partners Announces Additional Financing and Formation of Scientific Advisory Board

GRAND RAPIDS, MI (October 16, 2014): Tetra Discovery Partners (“Tetra”), a drug discovery company developing a portfolio of innovative drugs for psychiatric, neurological and inflammatory diseases, today announced additional private financing. The company has received additional financing from previous seed investor Grand Angels, as well as an investment by Johnson & Johnson Development Corporation (JJDC).

Tetra additionally announced the formation of its Scientific Advisory Board, comprised of four prominent experts in the field of neuroscience and psychiatric drug development:  more

Tetra Discovery to Collaborate with The Broad Institute’s Stanley Center for Psychiatric Research To Pursue Schizophrenia Therapeutics

GRAND RAPIDS, MI (April 9, 2014): Tetra Discovery Partners LLC, a drug discovery company developing a portfolio of innovative drugs for neurological and inflammatory diseases, announced today that the company has entered into a drug development collaboration with the Broad Institute’s Stanley Center for Psychiatric Research in Cambridge, MA. The focus of the collaboration will be to test the potential of Tetra’s drug candidates for improving cognition in the Stanley Center’s proprietary genetic models relating to schizophrenia.  more

Tetra high school intern is semifinalist in the 2014 Intel Science Talent Search

GRAND RAPIDS, MI (January 22, 2014):  Emily D’Amato from Forest Hills Central High School, Grand Rapids, MI was selected as a semi-finalist in the 2014 Intel Science talent Search for her project conducted as an intern at Tetra, “The Development of Phosphodiesterase 4D Inhibitors with 3D Printing and Molecular Visualization Software for the Treatment of Acrodysostosis.”    more

Promising Life Science Start-up Continues Breaking Milestones with Business Assistance & Funding from a Collaboration of MI-based Programs

Grand Rapids, MI – October, 2013 – Leading inventor of Alzheimer’s disease treatments, Dr. Mark Gurney, continues to grow his West Michigan-based lean, biotech start-up – Tetra Discovery Partners, LLC (Tetra) – through the support of a collaboration of Michigan entrepreneurial and funding programs. Tetra is working on the development of three new drugs targeted at improving treatments for Alzheimer’s, depression, and traumatic brain injuries.  more


Latest Financing to Accelerate Development of Alzheimer’s Drug

GRAND RAPIDS, Mich., Sept. 30, 2013 – Tetra Discovery Partners, a leader in the design of new therapeutics for major neurological conditions based on PDE4 modulation in the brain, today announced it has closed a $1,041,000 seed investment led by Grand Angels, a Grand Rapids, Mich.-based investment group.  more